ArticleInfection and drug resistance2024
T Lymphocyte Mitochondrial Markers as Independent Risk Factors for Poor Prognosis of COVID-19.
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alterations in T lymphocyte subsets and mitochondrial-related parameters in patients with chronic kidney disease.Frontiers in medicine · 2026Article
- Monitoring mitochondrial function in peripheral T cells to assess immune status and graft health after kidney transplantation.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2) primarily targets mitochondria. However, the description of mitochondrial signaling in immune cells remains limited in COVID-19. This study aimed to elucidate the pivotal roles played by immune cells and mitochondria in the pathogenesis of COVID-19 and the resulting clinical outcomes. Methods: We obtained epidemiological characteristics, laboratory parameters and T cell mitochondrial damage indicators in 296 COVID-19 patients. And we further evaluated the predictive value of novel T lymphocyte mitochondrial markers and conventional immune inflammatory markers as clinical outcomes in COVID-19 patients. Finally, Binary logistic regression analysis was conducted to identify the independent risk factors associated with the prognosis of patients with COVID-19. Results: The severe group exhibited lower counts of Mito+CD3+, Mito+CD4+, and Mito+CD8+ cells compared to the non-severe group. Significantly higher positive rates of CD3+, CD3+CD4+, and CD3+CD8+T cell mitochondrial damage were observed in the severe group compared to the non-severe group. The CD3+CD8+T cells MMP-low% had the highest AUC value of 0.864 (95% CI =0.794-0.934) to evaluate COVID-19 outcome. Binary logistic regression analysis showed that CD3+T cells MMP-low%, CD3+CD4+T cells MMP-low% and CD3+CD8+T cells MMP-low% were independent risk factors for adverse outcomes in COVID-19 patients. Conclusion: Our research suggests that a substantial proportion of COVID-19 patients exhibited mitochondrial impairment with T-lymphocyte. T cells mitochondrial markers can serve as predictive factors and independent risk factors for predicting adverse outcomes in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.